Switchover to generic cyclosporine in stable renal transplant recipients: A single unit experience

Nephrology

Volumn 9, Issue 6, 2004, Pages 418-421

  Talaulikar, Girish S ^a   Gallagher, Martin P ^a   Carney, Gavin M ^a   Jadeer, Asad A ^a   Falk, Michael C ^a   Hiremagalur, Balaji ^a  

^a CANBERRA HOSPITAL   (Australia)

Author keywords

Bioequivalence; Cyclosporine; Generic medications; Pharmacokinetics; Renal transplant

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; CYSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MATHEMATICAL ANALYSIS; MICROEMULSION; PRIORITY JOURNAL; SIDE EFFECT;

CROSS-OVER STUDIES; CYCLOSPORINE; DRUGS, GENERIC; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 12244291038     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2004.00335.x     Document Type: Article

References (13)

1. Alloway RR. Generic immunosuppressant use in solid organ transplantation. Transplant. Proc. 1999; 31 (Suppl. 3A): 2S-5S.
2. Nankivell B, Gruenewald SM, Allen R, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683-9.
3. Christians U, First MR, Benet L. Recommendations for bioequivalence testing of cyclosporinee generics revisited. Ther. Drug. Monit. 2000; 32: 330-45.
4. Therapeutic Goods Administration. CPMP guideline as adopted in Australia by the TGA - with April 2002 amendment. Available from URL: http://www.health. gov.au/tga/docs/pdf/euguide/ewp/14019entga.pdf
5. Johnston A, Holt DW. Bioequivalence criteria for cyclosporine. Transplant. Proc. 1999; 31: 1649-53.
6. US Department of Health and Human Services: Food and Drug Administration. Statistical Approaches to Establishing Bioequivalence. January 2001. Available from URL: http://www.fda.gov/cder/guidance/index.htm
7. First MR, Schroeder TJ, Monaco AP et al. cyclosporine bioavailability: dosing implications and impact on clinical outcomes in select transplant sub-populations. Clin. Transplant. 1996; 10: 55-9.
8. Lee YJ, Chung SJ, Shim CK. Bioequivalence of Neoplanta capsule to Sandimmune Neoral, microemulsion formulations of cyclosporinee A in human subjects. Int. J. Clin. Pharmacol. Ther. 1998; 36: 210-15.
9. Kim SC, Han DJ. Neoplanta as a new microemulsion formula of cyclosporinee in renal transplantation: comparative study with Neoral for efficacy and safety. Transplant. Proc. 1998; 30: 3547-8.
10. Park MS, Yu NC, Kim YS, Lee H, Kim KH. Bioequivalence study of CIPOL-N (cyclosporinee microemulsion preparation) in healthy adults. Transplant. Proc. 1998; 30: 3541-6.
11. First MR, Weiskittel P, Burton M et al. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a novel cyclosporinee formulation, using a dose-normalized equivalence method. Transplant. Proc. 1998; 30: 1701-5.
12. First MR, Alloway R, Schroeder TJ. Development of Sang-35: a cyclosporinee formulation bioequivalent to Neoral. Clin. Transplant. 1998; 12: 518-24.
13. Alloway RR, Isaacs R, Lake K et al. Report of the American society of transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am. J. Transplant. 2003; 3: 1211-15.